Investigating the purpose of prelamin A processing

References

• Muchir A, Worman HJ. The nuclear envelope and human disease. Physiology (Bethesda) 2004; 19:309 - 314
   PubMed Web of Science ®Google Scholar
• Lin F, Worman HJ. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem 1993; 268:16321 - 16326
   PubMed Web of Science ®Google Scholar
• Hutchison CJ, Worman HJ. A-type lamins: guardians of the soma?. Nat Cell Biol 2004; 6:1062 - 1067
   PubMed Web of Science ®Google Scholar
• Wilson KL. The nuclear envelope, muscular dystrophy and gene expression. Trends Cell Biol 2000; 10:125 - 129
   PubMed Web of Science ®Google Scholar
• Sullivan T, Escalante-Alcalde D, Bhatt H, Anver M, Bhat N, Nagashima K, et al. Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. J Cell Biol 1999; 147:913 - 920
   PubMed Web of Science ®Google Scholar
• Wolf CM, Wang L, Alcalai R, Pizard A, Burgon PG, Ahmad F, et al. Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. J Mol Cell Cardiol 2008; 44:293 - 303
   PubMed Web of Science ®Google Scholar
• Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, Kamm RD, et al. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest 2004; 113:370 - 378
   PubMed Web of Science ®Google Scholar
• Burke B, Stewart CL. Life at the edge: the nuclear envelope and human disease. Nat Rev Mol Cell Biol 2002; 3:575 - 585
   PubMed Web of Science ®Google Scholar
• Fisher DZ, Chaudhary N, Blobel G. cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. Proc Natl Acad Sci USA 1986; 83:6450 - 6454
   PubMed Web of Science ®Google Scholar
• Mounkes LC, Burke B, Stewart CL. The A-Type lamins: nuclear structural proteins as a focus for muscular dystrophy and cardiovascular diseases. Trends Cardiovasc Med 2001; 11:280 - 285
   PubMed Web of Science ®Google Scholar
• Casey PJ. Biochemistry of protein prenylation. J Lipid Res 1992; 33:1731 - 1740
   PubMed Web of Science ®Google Scholar
• Casey PJ, Seabra MC. Protein prenyltransferases. J Biol Chem 1996; 271:5289 - 5292
   PubMed Web of Science ®Google Scholar
• Clarke S. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem 1992; 61:355 - 386
   PubMed Web of Science ®Google Scholar
• Davies BS, Fong LG, Yang SH, Coffinier C, Young SG. The posttranslational processing of prelamin A and disease. Annu Rev Genomics Hum Genet 2009; 10:153 - 174
   PubMed Web of Science ®Google Scholar
• Sinensky M, Fantle K, Trujillo M, McLain T, Kupfer A, Dalton M. The processing pathway of prelamin A. J Cell Sci 1994; 107:61 - 67
   PubMed Web of Science ®Google Scholar
• Bergo MO, Gavino B, Ross J, Schmidt WK, Hong C, Kendall LV, et al. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness and a prelamin A processing defect. Proc Natl Acad Sci USA 2002; 99:13049 - 13054
   PubMed Web of Science ®Google Scholar
• Corrigan DP, Kuszczak D, Rusinol AE, Thewke DP, Hrycyna CA, Michaelis S, et al. Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24. Biochem J 2005; 387:129 - 138
   PubMed Web of Science ®Google Scholar
• Fong LG, Ng JK, Meta M, CotÇ N, Yang SH, Stewart CL, et al. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc Natl Acad Sci USA 2004; 101:18111 - 18116
   PubMed Web of Science ®Google Scholar
• Pendas AM, Zhou Z, Cadinanos J, Freije JMP, Wang J, Hultenby K, et al. Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet 2002; 31:94 - 99
   PubMed Web of Science ®Google Scholar
• Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003; 423:293 - 298
   PubMed Web of Science ®Google Scholar
• Dechat T, Shimi T, Adam SA, Rusinol AE, Andres DA, Spielmann HP, et al. Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging. Proc Natl Acad Sci USA 2007; 104:4955 - 4960
   PubMed Web of Science ®Google Scholar
• Yang SH, Andres DA, Spielmann HP, Young SG, Fong LG. Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated. J Clin Invest 2008; 118:3291 - 3300
   PubMed Web of Science ®Google Scholar
• Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, et al. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2004; 101:8963 - 8968
   PubMed Web of Science ®Google Scholar
• Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN, et al. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2005; 102:12879 - 12884
   PubMed Web of Science ®Google Scholar
• Glynn MW, Glover TW. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet 2005; 14:2959 - 2969
   PubMed Web of Science ®Google Scholar
• Mallampalli MP, Huyer G, Bendale P, Gelb MH, Michaelis S. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2005; 102:14416 - 14421
   PubMed Web of Science ®Google Scholar
• Toth JI, Yang SH, Qiao X, Beigneux AP, Gelb MH, Moulson CL, et al. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci USA 2005; 102:12873 - 12878
   PubMed Web of Science ®Google Scholar
• Yang SH, Bergo MO, Toth JI, Qiao X, Hu Y, Sandoval S, et al. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci USA 2005; 102:10291 - 10296
   PubMed Web of Science ®Google Scholar
• Yang SH, Meta M, Qiao X, Frost D, Bauch J, Coffinier C, et al. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest 2006; 116:2115 - 2121
   PubMed Web of Science ®Google Scholar
• Yang SH, Chang SY, Andres DA, Spielmann HP, Young SG, Fong LG. Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria. J Lipid Res 2010; 51:400 - 405
   PubMed Web of Science ®Google Scholar
• Yang SH, Qiao X, Fong LG, Young SG. Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. Biochim Biophys Acta 2008; 1781:36 - 39
   PubMed Web of Science ®Google Scholar
• Fong LG, Frost D, Meta M, Qiao X, Yang SH, Coffinier C, et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006; 311:1621 - 1623
   PubMed Web of Science ®Google Scholar
• Davies BS, Barnes RH 2nd, Tu Y, Ren S, Andres DA, et al. An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum Mol Genet 2010; 19:2682 - 2694
   PubMed Web of Science ®Google Scholar
• DeBusk FL. The Hutchinson-Gilford progeria syndrome. Report of 4 cases and review of the literature. J Pediatr 1972; 80:697 - 724
   PubMed Web of Science ®Google Scholar
• Fernandez-Palazzi F, McLaren AT, Slowie DF. Report on a case of Hutchinson-Gilford progeria, with special reference to orthopedic problems. Eur J Pediatr Surg 1992; 2:378 - 382
   PubMed Web of Science ®Google Scholar
• Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, et al. Changes in gene expression in the intact human heart. Downregulation of alphamyosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 1997; 100:2315 - 2324
   PubMed Web of Science ®Google Scholar
• Bonne G, Barletta MRD, Varnous S, Becane HM, Hammouda EH, Merlini L, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999; 21:285 - 288
   PubMed Web of Science ®Google Scholar
• Muchir A, Bonne G, van der Kooi AJ, van Meegen M, Baas F, Bolhuis PA, et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet 2000; 9:1453 - 1459
   PubMed Web of Science ®Google Scholar
• Vytopil M, Benedetti S, Ricci E, Galluzzi G, Dello Russo A, Merlini L, et al. Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomuscular phenotypes. J Med Genet 2003; 40:132
   PubMed Web of Science ®Google Scholar
• Arimura T, Helbling-Leclerc A, Massart C, Varnous S, Niel F, Lacene E, et al. Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum Mol Genet 2005; 14:155 - 169
   PubMed Web of Science ®Google Scholar
• Mounkes LC, Kozlov SV, Rottman JN, Stewart CL. Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice. Hum Mol Genet 2005; 14:2167 - 2180
   PubMed Web of Science ®Google Scholar
• Fong LG, Ng JK, Lammerding J, Vickers TA, Meta M, CotÇ N, et al. Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest 2006; 116:743 - 752
   PubMed Web of Science ®Google Scholar
• Yang SH, Qiao X, Farber E, Chang SY, Fong LG, Young SG. Eliminating the synthesis of mature lamin A reduces disease phenotypes in mice carrying a Hutchinson-Gilford Progeria Syndrome allele. J Biol Chem 2008; 283:7094 - 7099
   PubMed Web of Science ®Google Scholar
• Beck LA, Hosick TJ, Sinensky M. Incorporation of a product of mevalonic acid metabolism into proteins of Chinese hamster ovary cell nuclei. J Cell Biol 1988; 107:1307 - 1316
   PubMed Web of Science ®Google Scholar
• Lutz RJ, Trujillo MA, Denham KS, Wenger L, Sinensky M. Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina. Proc Natl Acad Sci USA 1992; 89:3000 - 3004
   PubMed Web of Science ®Google Scholar
• Hennekes H, Nigg EA. The role of isoprenylation in membrane attachment of nuclear lamins. A single point mutation prevents proteolytic cleavage of the lamin A precursor and confers membrane binding properties. J Cell Sci 1994; 107:1019 - 1029
   PubMed Web of Science ®Google Scholar
• Lee R, Chang SY, Trinh H, Tu Y, White AC, Davies BS, et al. Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes. Hum Mol Genet 2010; 19:1603 - 1617
   PubMed Web of Science ®Google Scholar
• Coffinier C, Jung HJ, Li Z, Nobumori C, Yun UJ, Farber EA, et al. Direct synthesis of lamin A, bypassing prelamin a processing, causes misshapen nuclei in fibroblasts but no detectable pathology in mice. J Biol Chem 2010; 285:20818 - 20826
   PubMed Web of Science ®Google Scholar
• Beck LA, Hosick TJ, Sinensky M. Isoprenylation is required for the processing of the lamin A precursor. J Cell Biol 1990; 110:1489 - 1499
   PubMed Web of Science ®Google Scholar
• Vorburger K, Kitten GT, Nigg EA. Modification of nuclear lamin proteins by a mevalonic acid derivative occurs in reticulocyte lysates and requires the cysteine residue of the C-terminal CXXM motif. EMBO J 1989; 8:4007 - 4013
   PubMed Web of Science ®Google Scholar
• Weber K, Plessmann U, Traub P. Maturation of nuclear lamin A involves a specific carboxy-terminal trimming, which removes the polyisoprenylation site from the precursor; implications for the structure of the nuclear lamina. FEBS Lett 1989; 257:411 - 414
   PubMed Web of Science ®Google Scholar
• Kieran MW, Gordon L, Kleinman M. New approaches to progeria. Pediatrics 2007; 120:834 - 841
   PubMed Web of Science ®Google Scholar